Publication at Faculty of Medicine in Pilsen |
2014
Abstract
The inhibition oř platelet receptor P2Y12 is considered to bea basic step in the treatment of patients with acute coronary syndromes (ACS). Clopidogrel that has been widely used to date is currently being replaced with new antiplatelet drugs prasugrel and ticagrelor with a more rapid onset of therapeutic effect and more expressed antiplatelet activity.
According to the recent guidelines of the European Society of Cardiology forthe management oř ACS patients with and without ST segment elevations, these drugs have a higher class oř recommen-dation than clopidogrel. The results of dinical trials confirmed a significant reduction in ischemic complications in ACS patients.